BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...the option to acquire Corus Pharma Inc. ; (B) Cayston sales are reported grouped with Hepsera...
BioCentury | Apr 15, 2013
Clinical News

GS 840 adefovir dipivoxil data

...drug arose (see Clinical Status, B10). Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS 840 adefovir dipivoxil...
BioCentury | Jun 13, 2011
Company News

Gilead infectious, cardiovascular news

...a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Hepsera...
...Truvada and Edurant rilpivirine; pulmonary arterial hypertension (PAH) drug Letairis ambrisentan; and HBV drug Hepsera adefovir dipivoxil. WIR...
BioCentury | Jun 10, 2011
Company News

Gilead receives subpoena

...rilpivirine, as well as pulmonary arterial hypertension (PAH) drug Letairis ambrisentan and HBV drug Hepsera adefovir dipivoxil...
BioCentury | Feb 14, 2011
Clinical News

Hepsera adefovir dipivoxil infectious data

...Hepsera plus Pegasys peginterferon alfa-2a, 2 patients receiving placebo plus Pegasus, and 0 patients receiving Hepsera...
...at week 72. Data were published in the New England Journal of Medicine. Gilead markets Hepsera...
...Basel, Switzerland) markets Pegasys. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Hepsera adefovir dipivoxil ( GS 840...
BioCentury | Jan 3, 2011
Strategy

Arresto's development

...II GS 9310/11 inhaled fosfomycin/ tobramycin CF/chronic obstructive pulmonary disease (COPD) Ph II Liver Hepsera adefovir dipivoxil...
BioCentury | Nov 8, 2010
Clinical News

Viread tenofovir disoproxil fumarate: Additional Phase III data

...<400 copies/mL) at week 192 vs. 100% of patients who were switched to Viread from Hepsera...
...Viread previously met the study's primary endpoint of a significant increase in responses compared with Hepsera...
...see BioCentury, June 11, 2007). Gilead markets Viread to treat HIV and HBV infections, and Hepsera...
BioCentury | Nov 8, 2010
Clinical News

Viread tenofovir disoproxil fumarate: Additional Phase III data

...<400 copies/mL) at week 192 vs. 99% of patients who were switched to Viread from Hepsera...
...Viread previously met the study's primary endpoint of a significant increase in responses compared with Hepsera...
...see BioCentury, July 2, 2007). Gilead markets Viread to treat HIV and HBV infections, and Hepsera...
BioCentury | Dec 7, 2009
Company News

Gilead, GlaxoSmithKline sales and marketing update

...tenofovir to a 2002 deal under which GSK received exclusive rights to Gilead's HBV drug Hepsera...
BioCentury | Nov 9, 2009
Clinical News

Baraclude entecavir: Phase IIIb data

...of a significantly greater mean reduction from baseline in HBV DNA at week 24 vs. Hepsera...
...16% of Hepsera patients. At 48 weeks, 57% and 20% of patients on Baraclude and Hepsera...
...achieved ALT normalization at 24 and 48 weeks, respectively, compared to 39% and 46% of Hepsera...
Items per page:
1 - 10 of 209